Pharmaceuticals News

– Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially...

VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse...

Selskabsmeddelelse 20/2026                                                                   11. august 2026                                                              Storaktionærmeddelelse i...

Boehringer Ingelheim announced today that it has acquired Evax AG, a Swiss biotech company focused on equine health. Founded more than a decade ago at the University of Zurich, Evax has been...

Company announcement no. 30 - 2611 August 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...

Ad hoc announcement pursuant to Art. 53 LR The DEA states that dual orexin receptor antagonists “do not produce physical or psychological dependence”Lower schedule expected to enhance patient access...

Next-gen all-in-one performance supplement NORTH launches globally. 30+ athlete co-owners. Pre-sales open now. Full launch September 2026.

MediPharm Labs is pleased to announce the company will release its 2026 second quarter financial results before markets open on Thursday, August 13 2026.

Seal Beach, CA, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Oh!Nutrition, a California-based nutritional product development company, today announced Oh!mino® Muscle Synthesis Activator, an essential amino...

Initiated a Phase 1 study of SCY-770, a first-in-class, potent and direct AMPK activator for treatment of ADPKD; topline data are expected in Q3 2026 and are anticipated to inform dose selection for...